Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 11/20 | 0.52 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6009617 | 0.87 | NR1H3 (0.56) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12704623 | 0.86 | NR1H3 (0.49) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12704624 | 0.85 | PTGS1 (0.49) | PTGS1NR1H3PTPN1 | |
| SCHEMBL267021 | 0.83 | NR1H3 (0.69) | PTGS1NR1H3PTPN1 | |
| SCHEMBL12450175 | 0.83 | NR1H3 (0.69) | PTGS1NR1H3PTPN1 | |
| SCHEMBL260903 | 0.83 | NR1H3 (0.69) | PTGS1NR1H3PTPN1 | |
| SCHEMBL823262 | 0.83 | NR1H3 (0.46) | PTGS1NR1H3PTPN1KARS1 | |
| SCHEMBL10224030 | 0.83 | NR1H3 (0.71) | PTGS1NR1H3PTPN1 | |
| SCHEMBL280222 | 0.80 | PTGS1 (0.64) | PTGS1NR1H3PTPN1 | |
| SCHEMBL6008180 | 0.77 | PTGS1 (0.58) | PTGS1NR1H3PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1912932-B1 | INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-A MODULATORS; SYNTHESES OF SUCH MODULATORS AND METHODS OF USING SUCH MODULATORS | NEREUS PHARMACEUTICALS INC (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2311795-A2 | Interleukin-1 and tumor necrosis factor-alpha modulators; syntheses of such modulators and methods of using such modulators | Nereus Pharmaceuticals, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |